STAA News and Press, STAAR Surgical Company

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on...

New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction with EVO ICL is now the leading procedure for U.S. patients with -8.0 diopters...

Iamgold Corporation (IAG) is expected to report $0.55 for Q4 2025 Bel Fuse Inc (BELFB) is expected to report $1.44 for Q4 2025 Beta Bionics Inc. (BBNX) is expected to report $-0.42 for Q4 2025 TPG RE Finance Trust Inc. (TRTX) is expected to report $0.25 for Q4 2025 CEVA Inc. (CEVA...

Klaviyo Inc. Series A (KVYO) is expected to report $0.04 for Q4 2025 Diodes Incorporated (DIOD) is expected to report $0.26 for Q4 2025 CRISPR Therapeutics AG (CRSP) is expected to report $-1.15 for Q4 2025 Brighthouse Financial Inc. (BHF) is expected to report $5.19 for Q4 2025 B...

Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ® Lenses (EVO ICL™) for vision...

2026-01-15 09:43:23 ET More on STAAR Surgical STAAR Surgical: Alcon Raises Its Bid, But Obstacles Remain STAAR Surgical holder Yunqi Capital purchased 750K shares for $21.53 Alcon terminates agreement to purchase STAAR Surgical Seeking Alpha’s Quant Ra...

Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Compan...

2026-01-08 13:41:12 ET More on STAAR Surgical, Alcon STAAR Surgical: Alcon Raises Its Bid, But Obstacles Remain Alcon: Some Premium Coming Out Of This Quality Play Alcon Inc. (ALC) Q3 2025 Earnings Call Transcript Alcon terminates agreement to purchase STAAR ...